> top > projects > Inflammaging > docs > PubMed:32178765 > annotations
Inflammaging  

PubMed:32178765 JSONTXT 9 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T1 0-206 Sentence denotes Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial.
T1 0-206 Sentence denotes Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial.
T2 207-218 Sentence denotes BACKGROUND:
T2 207-218 Sentence denotes BACKGROUND:
T3 219-328 Sentence denotes Many patients with psoriatic arthritis have an inadequate response to tumor necrosis factor (TNF) inhibitors.
T3 219-328 Sentence denotes Many patients with psoriatic arthritis have an inadequate response to tumor necrosis factor (TNF) inhibitors.
T4 329-534 Sentence denotes Guselkumab, a specific inhibitor of interleukin-23 (IL-23) via IL-23 p19 subunit binding, significantly improved psoriatic arthritis signs and symptoms with an acceptable safety profile in a phase 2 trial.
T4 329-534 Sentence denotes Guselkumab, a specific inhibitor of interleukin-23 (IL-23) via IL-23 p19 subunit binding, significantly improved psoriatic arthritis signs and symptoms with an acceptable safety profile in a phase 2 trial.
T5 535-543 Sentence denotes METHODS:
T5 535-543 Sentence denotes METHODS:
T6 544-874 Sentence denotes This multicentre, double-blind, randomised, placebo-controlled, phase 3 trial was done at 86 sites in 13 countries across Asia, Australasia, Europe, and North America and enrolled adults with active psoriatic arthritis (at least three swollen and three tender joints; and C-reactive protein ≥0·3 mg/dL) despite standard therapies.
T6 544-874 Sentence denotes This multicentre, double-blind, randomised, placebo-controlled, phase 3 trial was done at 86 sites in 13 countries across Asia, Australasia, Europe, and North America and enrolled adults with active psoriatic arthritis (at least three swollen and three tender joints; and C-reactive protein ≥0·3 mg/dL) despite standard therapies.
T7 875-1176 Sentence denotes Eligibility criteria included inadequate response to or intolerance of standard treatment, including at least 4 months of apremilast, at least 3 months of non-biologic disease-modifying antirheumatic drugs (DMARDs), or at least 4 weeks of non-steroidal anti-inflammatory drugs for psoriatic arthritis.
T7 875-1176 Sentence denotes Eligibility criteria included inadequate response to or intolerance of standard treatment, including at least 4 months of apremilast, at least 3 months of non-biologic disease-modifying antirheumatic drugs (DMARDs), or at least 4 weeks of non-steroidal anti-inflammatory drugs for psoriatic arthritis.
T8 1177-1266 Sentence denotes About 30% of study participants could have previously received one or two TNF inhibitors.
T8 1177-1266 Sentence denotes About 30% of study participants could have previously received one or two TNF inhibitors.
T9 1267-1526 Sentence denotes Patients were randomly assigned (1:1:1, computer-generated permuted blocks; stratified by baseline DMARD and previous TNF inhibitor use) to subcutaneous guselkumab 100 mg every 4 weeks; guselkumab 100 mg at weeks 0, 4, then every 8 weeks; or matching placebo.
T9 1267-1526 Sentence denotes Patients were randomly assigned (1:1:1, computer-generated permuted blocks; stratified by baseline DMARD and previous TNF inhibitor use) to subcutaneous guselkumab 100 mg every 4 weeks; guselkumab 100 mg at weeks 0, 4, then every 8 weeks; or matching placebo.
T10 1527-1696 Sentence denotes The primary endpoint was American College of Rheumatology 20% improvement (ACR20) at week 24 in all patients per assigned treatment group using non-responder imputation.
T10 1527-1696 Sentence denotes The primary endpoint was American College of Rheumatology 20% improvement (ACR20) at week 24 in all patients per assigned treatment group using non-responder imputation.
T11 1697-1756 Sentence denotes Safety was assessed in all patients per treatment received.
T11 1697-1756 Sentence denotes Safety was assessed in all patients per treatment received.
T12 1757-1842 Sentence denotes This trial is registered at ClinicalTrials.gov, NCT03162796 (active, not recruiting).
T12 1757-1842 Sentence denotes This trial is registered at ClinicalTrials.gov, NCT03162796 (active, not recruiting).
T13 1843-1852 Sentence denotes FINDINGS:
T13 1843-1852 Sentence denotes FINDINGS:
T14 1853-2054 Sentence denotes From Aug 28, 2017, to Aug 17, 2018, we screened 624 patients, of whom 381 were randomly assigned and treated with guselkumab every 4 weeks (n=128), guselkumab every 8 weeks (n=127), or placebo (n=126).
T14 1853-2054 Sentence denotes From Aug 28, 2017, to Aug 17, 2018, we screened 624 patients, of whom 381 were randomly assigned and treated with guselkumab every 4 weeks (n=128), guselkumab every 8 weeks (n=127), or placebo (n=126).
T15 2055-2108 Sentence denotes 362 patients continued study treatment up to week 24.
T15 2055-2108 Sentence denotes 362 patients continued study treatment up to week 24.
T16 2109-2545 Sentence denotes The primary endpoint was met: ACR20 at week 24 was achieved by significantly greater proportions of patients in the guselkumab every 4 weeks group (76 [59%] of 128 [95% CI 50-68]) and every 8 weeks group (66 [52%] of 127 [43-61]) than in the placebo group (28 [22%] of 126 [15-30]), with percentage differences versus placebo of 37% (95% CI 26-48) for the every 4 weeks group and 30% (19-41) for the every 8 weeks group (both p<0·0001).
T16 2109-2545 Sentence denotes The primary endpoint was met: ACR20 at week 24 was achieved by significantly greater proportions of patients in the guselkumab every 4 weeks group (76 [59%] of 128 [95% CI 50-68]) and every 8 weeks group (66 [52%] of 127 [43-61]) than in the placebo group (28 [22%] of 126 [15-30]), with percentage differences versus placebo of 37% (95% CI 26-48) for the every 4 weeks group and 30% (19-41) for the every 8 weeks group (both p<0·0001).
T17 2546-2739 Sentence denotes Serious adverse events up to week 24 occurred in no patients receiving guselkumab every 4 weeks, four (3%) patients receiving guselkumab every 8 weeks, and five (4%) patients receiving placebo.
T17 2546-2739 Sentence denotes Serious adverse events up to week 24 occurred in no patients receiving guselkumab every 4 weeks, four (3%) patients receiving guselkumab every 8 weeks, and five (4%) patients receiving placebo.
T18 2740-2907 Sentence denotes Up to week 24, one patient in the placebo group died from cardiac failure and two had serious infections; no guselkumab-treated patient died or had serious infections.
T18 2740-2907 Sentence denotes Up to week 24, one patient in the placebo group died from cardiac failure and two had serious infections; no guselkumab-treated patient died or had serious infections.
T19 2908-2923 Sentence denotes INTERPRETATION:
T19 2908-2923 Sentence denotes INTERPRETATION:
T20 2924-3070 Sentence denotes Guselkumab demonstrated a favourable benefit-risk profile and might be an effective treatment option for patients with active psoriatic arthritis.
T20 2924-3070 Sentence denotes Guselkumab demonstrated a favourable benefit-risk profile and might be an effective treatment option for patients with active psoriatic arthritis.
T21 3071-3079 Sentence denotes FUNDING:
T21 3071-3079 Sentence denotes FUNDING:
T22 3080-3113 Sentence denotes Janssen Research and Development.
T22 3080-3113 Sentence denotes Janssen Research and Development.